A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3406-3416

  Muderspach, L ^a   Wilczynski, S ^a   Roman, L ^a   Bade, L ^a   Felix, J ^a   Small, L A ^a   Kast, W M ^a   Fascio, G ^a   Marty, V ^a   Weber, J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOKINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ARTICLE; CANCER GRADING; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HELPER CELL; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VACCINATION; VULVA CANCER; WART VIRUS;

ADULT; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; FREUND'S ADJUVANT; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS;

EID: 0033813525     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Natural history of cervical intraepithelial neoplasia
2. Dysplasia of the cervix: A prospective study of 206 cases
3. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia
4. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types
5. Human papillomaviruses and other influences on survival from cervical cancer in Panama
6. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes
7. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18
8. Continued expression of HPV 16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV 16 plus EJ-ras
9. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product
10. Serologic assays for the detection of HPV anti-bodies
11. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen
12. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA4
13. Vaccination with cytolytic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type 16 transformed cells
14. Protection against lethal Sendal vires infection by in vivo priming of vires specific cytotoxic T lymphocytes with a free synthetic peptide
15. In vivo priming of virus specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
16. Priming of influenza virus-specific cytotoxic T lymphocytes in vivo by short synthetic peptides
17. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide
18. CD8+ cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo
19. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histo-compatibility complex molecule-restricted murine cytotoxic T lymphocytes
20. Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carder free HIV synthetic peptides
21. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: Relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides
22. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
23. PBLs of early breast carcinoma patients of a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TcR ζ expression but are functionally impaired
24. Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract
25. Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe
26. Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix
27. Local immune response in persistent cervical dysplasia
28. Relationship between types of human papillomavirus and Langerhans' cells in cervical condyloma and intraepithelial neoplasia
29. Decreased expression of signal transduction ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer
30. Kiviat NBA cohort study of the risk of cervical intraepithelial neoplasia grade II or III in relation to papillomavirus infection
31. Correlative study of HPV, DNA, histopathology and morphometry in cervical condyloma and intraepithelial neoplasia
32. Identification of human papillomavirus in cervical swabs by deoxyribonucleic acid in situ hybridization
33. Human papillomaviruses and cervical carcinomas: Histologic features associated with different viral types
34. Adenocarcinoma of the cervix associated with human papilloma-viruses
35. Small cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18 associated cancer
36. Antibodies to FA, E6 and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV associated diseases and the normal population
37. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia
38. Serologic responses to human papillomavirus type 16 (HPV 16) virus-like particles in HPV-16 DNA positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain
39. T-cell proliferative responses to human papillomavirus type 16 peptides: Relationship to cervical intraepithelial neoplasia
40. T-cell proliferative responses against human papilloma-virus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection
41. Proliferative T-cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and healthy women
42. Proliferative T-cell responses to human papillomavirus type 16 L1 peptides in women with cervical dysplasia
43. Human T helper cell epitopes overlap B cell and cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16
44. Lymphoproliferative responses to human papillomavirus type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia
45. Differential T-helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study
46. Peptide engineering allows cytotoxic T-cell vaccination against human papillomavirus tumor antigen E6
47. Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16
48. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor
49. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I restricted protection to HPV16-induced tumor cells
50. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type-16 induced tumors
51. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201 binding peptides
52. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type-16 positive cervical lesions against a human leucocyte antigen A*0201-restricted E7 encoded epitope
53. Human papillomavirus-specific cytotoxic T-lymphocytes in patients with cervical intraepithelial neoplasia grade III
54. Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16 and 18 positive cervical cancer
55. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes
56. Cytotoxic T cell responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia
57. Generation of tumor specific cytotoxic T lymphocytes from peripheral blood of cervical cancer patients by in vitro restimulation with a synthetic human papillomavirus type 16 E7 epitope
58. Cell mediated immunologic responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
59. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial
60. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
61. Natural history of cervical squamous intraepithelial lesions: A meta-analysis
62. Immunohistochemical identification of Langerhans' cells in normal epithelium and in epithelial lesions of the uterine cervix
63. Selective recruitment of mature and immature dendritic cells by distinctive chemokines expressed in different anatomic sites
64. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma
65. Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas
66. Specific MHC class I down-regulation is an early event in cervical dysplasia associated with clinical progression